LPL Financial’s Immunome IMNM Stock Holding History

LPL Financial’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-17,450	Closed	-$255K	–	5368
2024 Q3	$255K	Buy	+17,450	New	+$248K	﹤0.01%	4560

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial's IMNM Position: Q4 2024 in Review

LPL Financial sold out of Immunome (IMNM) in Q4 2024, closing a stake of 17,450 shares — an estimated $255K sold.

LPL Financial first reported a position in IMNM in Q3 2024 and held it in 1 quarter. The position peaked at $255K in Q3 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

LPL Financial reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
LPL Financial sold 17,450 Immunome shares in Q4 2024, an estimated $255K.
LPL Financial first reported a position in Immunome in Q3 2024 and held it in 1 quarter.
LPL Financial's Immunome position peaked at $255K in Q3 2024.
120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on LPL Financial's 13F filing for Q4 2024, filed 11 Feb 2025.